In the ELISpot and ICS, we found that TCR+ VSTs and TCR8+ VSTs produced comparable levels of IFN-γ against the cognate survivin peptide (LML) or the HLA-A*02:01+ survivin+ leukemia cell line BV173, but anti-viral reactivities against CMV (NLV peptide, pp65 and IE1 pepmixes) and EBV (GLC and YVL peptides, LMP2 pepmix) were significantly reduced in TCR+ VSTs compared with NT VSTs. The gene discussed is IFNG; the disease is leukemia.